---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-035917"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2025-03-10T23:59:59+00:00"
generated_at: "2026-05-25T01:42:39.502828+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics FY2024 net loss $127.2M; cash runway into Q2 2026

## Summary
- Net loss $127.2M ($1.68/share) vs $121.8M ($2.02/share) in FY2023; R&D expense rose to $118.0M.
- Cash, equivalents and marketable securities $133.6M at Dec 31, 2024; runway into Q2 2026.
- PRT3789 showed 5 confirmed partial responses in NSCLC, gastric, esophageal cancer; safety acceptable.
- PRT7732 oral SMARCA2 degrader Phase 1 enrollment ongoing; interim data expected H2 2025.
- Bryant Lim named permanent CFO; company to seek partner for PRT2527 CDK9 program.

## SEC filing metadata
- accession: 0000950170-25-035917
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2025-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017025035917/0000950170-25-035917-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017025035917/prld-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-035917
- JSON: https://secwatch.observer/filing/0000950170-25-035917.json
- Plain text: https://secwatch.observer/filing/0000950170-25-035917.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.